Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

被引:627
作者
Taraseviciene-Stewart, L
Kasahara, Y
Alger, L
Hirth, P
McMahon, G
Waltenberger, J
Voelkel, NF
Tuder, RM
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA
[3] SUGEN Inc, S San Francisco, CA 94080 USA
[4] Univ Ulm, Med Ctr, Dept Internal Med 2, D-89081 Ulm, Germany
[5] Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Denver, CO 80262 USA
关键词
apoptosis; survival; selection; pulmonary vascular remodeling; angiogenesis;
D O I
10.1096/fj.00-0343com
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our understanding of the pathobiology of severe pulmonary hypertension, usually a fatal disease, has been hampered by the lack of information of its natural history. We have demonstrated that, in human severe pulmonary hypertension, the precapillary pulmonary arteries show occlusion by proliferated endothelial cells. Vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR-2) are involved in proper maintenance, differentiation, and function of endothelial cells. We demonstrate here that VEGFR-2 blockade with SU5416 in combination with chronic hypobaric hypoxia causes severe pulmonary hypertension associated with precapillary arterial occlusion by proliferating endothelial cells. Prior to and concomitant with the development of severe pulmonary hypertension, lungs of chronically hypoxic SU5416-treated rats show significant pulmonary endothelial cell death, as demonstrated by activated caspase 3 immunostaining and TUNEL. The broad caspase inhibitor Z-Asp-CH2-DCB prevents the development of intravascular pulmonary endothelial cell growth and severe pulmonary hypertension caused by the combination of SU5416 and chronic hypoxia.
引用
收藏
页码:427 / 438
页数:12
相关论文
共 32 条
[11]  
HALBOWER AC, 1994, LAB INVEST, V71, P149
[12]   Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src [J].
He, H ;
Venema, VJ ;
Guo, XL ;
Venema, RC ;
Marrero, MB ;
Caldwell, RB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (35) :25130-25135
[13]  
Jones PL, 1997, AM J PATHOL, V150, P1349
[14]   The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells [J].
Kroll, J ;
Waltenberger, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) :32521-32527
[15]   VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR) [J].
Kroll, J ;
Waltenberger, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 252 (03) :743-746
[16]   Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension [J].
Lee, SD ;
Shroyer, KR ;
Markham, NE ;
Cool, CD ;
Voelkel, NF ;
Tuder, RM .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (05) :927-934
[17]  
MEYRICK B, 1980, AM J PATHOL, V100, P151
[18]   Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium [J].
Morbidelli, L ;
Chang, CH ;
Douglas, JG ;
Granger, HJ ;
Ledda, F ;
Ziche, M .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 270 (01) :H411-H415
[19]   Vascular endothelial growth factor vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin [J].
Murohara, T ;
Horowitz, JR ;
Silver, M ;
Tsurumi, Y ;
Chen, DF ;
Sullivan, A ;
Isner, JM .
CIRCULATION, 1998, 97 (01) :99-107
[20]   EVE and beyond, retro and prospective insights [J].
Rabinovitch, M .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1999, 277 (01) :L5-L12